CSIMarket
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Income from Cont. Operations Growth by Quarter and Year

Atara Biotherapeutics,'s Income from Cont. Operations results by quarter and year




ATRA Income from Cont. Operations (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - -80.01 -35.31 -18.24
III Quarter September - -58.36 -31.10 -25.37
II Quarter June - -50.88 -27.43 -18.88
I Quarter March -66.26 -41.44 -25.65 -16.56
FY   -66.26 -230.69 -119.49 -79.05



ATRA Income from Cont. Operations first quarter 2019 Y/Y Growth Comment
Atara Biotherapeutics, Inc. in the first quarter recorded loss from continued operations of $ -66.26 millions.

According to the results reported in the first quarter, Atara Biotherapeutics, Inc. achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Atara Biotherapeutics, Inc.' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter.




ATRA Income from Cont. Operations ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Atara Biotherapeutics,'s first quarter 2019 Income from Cont. Operations $ -66.26 millions ATRA's Income Statement
Atara Biotherapeutics,'s first quarter 2018 Income from Cont. Operations $ -41.44 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Income from Cont. Operations Growth >>


ATRA Income from Cont. Operations (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Atara Biotherapeutics,'s Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's I. Quarter Q/Q Income from Cont. Operations Comment
Even if Atara Biotherapeutics, Inc. in the I. Quarter 2019 revealed loss from continued operations of $ -66.26 millions, some analyst said, that current results are improvement relative to the -80.01 millions in the forth quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Income from Cont. Operations growth. While Atara Biotherapeutics,'s Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's I. Quarter Q/Q Income from Cont. Operations Comment
Even if Atara Biotherapeutics, Inc. in the I. Quarter 2019 admitted loss from continued operations of $ -66.26 millions, it should be said, that current results show recovery relative to the -80.01 millions in the forth quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Income from Cont. Operations growth. While Atara Biotherapeutics,'s Income from Cont. Operations growth quarter on quarter, overall rank is .


Atara Biotherapeutics,'s 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
12 Months Ending
12 Months Ending
12 Months Ending
12 Months Ending
Cumulative Income from Cont. Operations 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
In the period, Atara Biotherapeutics,'s cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
In the period, Atara Biotherapeutics,'s cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ATRA's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ATRA's Competitors
Income from Cont. Operations Growth for Atara Biotherapeutics,'s Suppliers
Income from Cont. Operations Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2019 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2019
Abiomed Inc  100.72 %$ 100.725 millions
Penumbra Inc  90.38 %$ 90.384 millions
Jazz Pharmaceuticals Plc  85.26 %$ 85.256 millions
Cardiovascular Systems Inc  84.11 %$ 84.110 millions
Celgene Corp  82.62 %$ 82.624 millions
Neurometrix, Inc.  75.82 %$ 75.820 millions
Haemonetics Corporation  75.38 %$ 75.379 millions
Hill-rom Holdings, Inc.  73.68 %$ 73.684 millions
Catalent, Inc.  66.84 %$ 66.842 millions
Abbott Laboratories  64.30 %$ 64.303 millions
Pro Dex Inc  52.50 %$ 52.500 millions
Tenax Therapeutics, Inc.  37.07 %$ 37.072 millions
Meridian Bioscience Inc  34.15 %$ 34.153 millions
Innoviva, Inc.  31.95 %$ 31.945 millions
Medpace Holdings, Inc.  31.94 %$ 31.936 millions
Bio-rad Laboratories, Inc.  31.73 %$ 31.734 millions
Techcare Corp.  31.71 %$ 31.714 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HSGX's Profile

Stock Price

HSGX's Financials

Business Description

Fundamentals

Charts & Quotes

HSGX's News

Suppliers

HSGX's Competitors

Customers & Markets

Economic Indicators

HSGX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071